Every material Form 8-K 60 DEGREES PHARMACEUTICALS, INC. has filed with the SEC since October 06, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
60 Degrees Pharmaceuticals agreed on November 5, 2026, to offer inducement letters to holders of existing warrants, who would exercise 584,492 shares at a reduced $0.90 per share. The company expects gross proceeds of $526,042.80 before fees, and in exchange will issue new unregistered warrants for up to 1,168,984 shares, which could add to share count and dilute existing shareholders.
Holders would exercise existing warrants for 584,492 shares at a reduced $0.90 per share, with expected gross proceeds of $526,042.80 before fees.
New warrants for up to 1,168,984 shares, equal to 200% of the exercised shares, carry a $0.90 exercise price and cannot be exercised before stockholder approval.
H.C. Wainwright & Co. is placement agent, receiving a 7.5% cash fee, a 1.0% management fee and placement agent warrants for 43,837 shares.
Closing is expected on or about November 9, 2026, subject to customary conditions.
60 Degrees Pharmaceuticals announced clinical improvement and negative conventional PCR results in all five patients who completed treatment in its expanded access babesiosis study, with four of five also NAT-negative on a highly sensitive post-treatment test. The company says the study remains open pending potential discussions with the FDA, and the filing reports no financial results, so the update is clinical and regulatory rather than a measure of current business performance.
All five completed patients were much or very much improved and tested negative on conventional PCR
Four of five completed patients (80%) were nonreactive on post-treatment blood-donor NAT testing
Two additional patients remain on treatment, bringing total enrollment to seven
Tafenoquine is not FDA-approved for babesiosis; the hospital-setting randomized study is expected to unblind in January 2027
60 Degrees Pharmaceuticals furnished an updated investor presentation dated October 23, 2026, under Regulation FD. The deck covers its tafenoquine program for babesiosis, including a randomized hospital study that has completed enrollment at 30 subjects and is set to unblind in January 2027, with a potential regulatory filing planned for 2027.
Randomized hospital study enrolled 30 subjects as of October 1, 2026; blinded follow-up completes in early January 2027, followed by unblinding.
A pre-sNDA meeting with FDA is planned for late January 2027, after the hospital study unblinds.
A September 2026 statement of interest asked FDA for national-priority review; the presentation shows a potential sNDA filing in April or May 2027.
Early chronic-study screening showed 2 of 9 genus-level dPCR positives and 0 of 9 B. microti NAT positives.
60 Degrees Pharmaceuticals said it will stop enrolling its randomized hospital study of tafenoquine for severe babesiosis at 30 patients, three fewer than the 33 the data safety monitoring board (DSMB) recommended completing. The company cited limited statistical benefit from three more patients and the seasonal nature of the disease, which would delay unblinding to fall 2027. The DSMB's interim review identified no safety issues, but the filing states it did not establish whether the study met its endpoints.
As of October 1, 2026, 30 patients were enrolled against a planned 33
Primary and secondary endpoint results are expected in January 2027
The company will request a pre-sNDA meeting with the FDA in January 2027
Additional data from a separate expanded access study are expected in early November 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every 60 DEGREES PHARMACEUTICALS, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →